(Department of Physiotherapy and Rehabilitation, Acıbadem University Faculty of Health Sciences, İstanbul, Turkey)
(Department of Physiology, Marmara University School of Medicine, İstanbul, Turkey)
(Department of Histology and Embryology, İstanbul Medeniyet University School of Medicine, İstanbul, Turkey.)
(Department of Physiology, Marmara University School of Medicine, İstanbul, Turkey)
(Department of Histology and Embryology, Ege University School of Medicine, İzmir, Turkey)
(Department of Physiology, Marmara University School of Medicine, İstanbul, Turkey)
(Department of Histology and Embryology, Ege University School of Medicine, İzmir, Turkey)
Berrak Çağlayan YEĞEN
(Department of Physiology, Marmara University School of Medicine, İstanbul, Turkey)
Yıl: 2017Cilt: 28Sayı: 6ISSN: 1300-4948 / 2148-5607Sayfa Aralığı: 476 - 484İngilizce

123 2
Treatment with milk thistle extract (Silybum marianum), ursodeoxycholic acid, or their combination attenuates cholestatic liver injury in rats: Role of the hepatic stem cells
Fen > Tıp > Cerrahi
DergiAraştırma MakalesiErişime Açık
  • 1. Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv 2014; 32: 504-13.
  • 2. Nu-o-Lámbarri N, Barbero-Becerra VJ, Uribe M, Chávez-Tapia NC. Elevated cholesterol levels have a poor prognosis in a cholestasis scenario. J Biochem Mol Toxicol 2016 Aug 12. doi: 10.1002/jbt.21831. [Epub ahead of print].
  • 3. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36: 525-31.
  • 4. He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology 2011; 53: 548-57.
  • 5. Surai PF. Silymarin as a natural antioxidant: An overview of the current evidence and perspectives. Antioxidants 2015; 4: 204- 47.
  • 6. Karimi G, Vahabzadeh M, Lari P, Rashedinia M, Moshiri M. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci 2011; 14: 308-17.
  • 7. Bettini R, Gorini M. Use of ursodeoxycholic acid combined with silymarin in the treatment of chronic ethyl-toxic hepatopathy. Clin Ter 2002; 153: 305-7.
  • 8. Thorgeirsson SS. Hepatic stem cells in liver regeneration. FASEB J 1996; 10: 1249-56.
  • 9. Baumann U, Crosby HA, Ramani P, Kelly DA, Strain AJ. Expression of the stem cell factor receptor c-kit in normal and diseased pediatric liver: Identification of a human hepatic progenitor cell? Hepatology 1999; 30: 112-7.
  • 10. Omori M, Evarts RP, Omori N, Hu Z, Marsden ER, Thorgeirsson SS. Expression of α-fetoprotein and stem cell factor/c-kit system in bile duct ligated young rats. Hepatology 1997; 25: 1115- 22.
  • 11. Kurtel H, Granger DN, Tso P, Grisham MB. Vulnerability of intestinal interstitial fluid to oxidant stress. Am J Physiol 1992; 263: 573-8.
  • 12. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982; 78: 206-9.
  • 13. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
  • 14. Chen T, Shen L, Yu J, et al. Rapamycin and other longevitypromoting compounds enhance the generation of mouse induced pluripotent stem cells. Aging Cell 2011; 10: 908-11.
  • 15. Uslu S, Oktem G, Uysal A, Soner BC, Arbak S, Ince U. Stem cell and extracellular matrix-related molecules increase following melatonin treatment in the skin of postmenopausal rats. Cell Biol Int 2014; 38: 924-32.
  • 16. Ionica FE, Mogoanta L, Nicola GC, et al. Antifibrotic action of telmisartan in experimental carbon tetrachloride-induced liver fibrosis in Wistar rats. Rom J Morphol Embryol 2016; 57:1261-72.
  • 17. Lee SJ, Park JB, Kim KH, et al. Immunohistochemical study for the origin of ductular reaction in chronic liver disease. Int J Clin Exp Pathol 2014; 7: 4076-85.
  • 18. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. New Engl J Med 1994; 330: 1342-7.
  • 19. Hajiani EH, Hashemi SJ. Comparison of therapeutic effects of silymarin and vitamin E in nonalcoholic fatty liver disease: results of an open labele, prospective, randomized study. JJNPP 2009; 4: 8-14.
  • 20. Aksu B, Umit H, Kanter M, et al. Effects of methylene blue in reducing cholestatic oxidative stress and hepatic damage after bile-duct ligation in rats. Acta Histochem 2010; 112: 259-69.
  • 21. Ljubuncic P, Tanne Z, Bomzon A. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci 2000; 45: 1921-8.
  • 22. Sokolovic D, Nikolic J, Kocic G, et al. The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation. Drug Chem Toxicol 2013; 36: 141-8.
  • 23. Bilgin BC, Tokgoz S, Cetinkunar S, et al. The protective effect of silymarin on cholestatic liver injury. Acta Medica Mediterr 2015; 31: 953-9.
  • 24. Czaja, AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20: 2515-32.
  • 25. Lee BS, Kim NJ, Jeong HY, Lee HY, Kang DY, Noh SM. Changes in serum cytokine concentration: a morphological study of liver cirrhosis induced by common bile duct ligation in rats. Kor J Intern Med 2003; 18: 6-12.
  • 26. Jeong DH, Lee GP, Jeong WI, et al. Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCl (4)-induced hepatic fibrosis. World J Gastroenterol 2005; 11: 1141-8.
  • 27. Liang TJ, Yuan JH, Tan YR, et al. Effect of ursodeoxycholic acid on TGF beta1/Smad signaling pathway in rat hepatic stellate cells. Chin Med J 2009; 122: 1209-13.
  • 28. Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci U S A 2001; 98: 10716-21.
  • 29. Shamblott MJ, Axelman J, Wang S, et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A 1998; 95: 13726-31.
  • 30. Russo FP, Parola M. Stem cells in liver failure. Best Pract Res Clin Gastroenterol 2005; 26: 35-45.
  • 31. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
  • 32. Koestenbauer S, Zech NH, Juch H, Vanderzwalmen P, Schoonjans L, Dohr G. Embryonic stem cells: similarities and differences between human and murine embryonic stem cells. Am J Reprod Immunol 2006; 55: 169-80.
  • 33. Schöler HR, Hatzopoulos AK, Balling R, Suzuki N, Gruss P. A family of octamer-specific proteins present during mouse embryogenesis: evidence for germline-specific expression of an Oct factor. EMBO J 1989; 8: 2543-50.
  • 34. Zeller KI, Jegga AG, Aronow BJ, O’Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003; 4: 69.
  • 35. Yin C, Evason KJ, Asahina K, Stainier DY. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest 2013; 123: 1902-10.
  • 36. Chu HH, Cho BH, Song JS, Kim KM, Moon WS. C-KIT-positive undifferentiated tumor of the liver: A case report. Oncol Lett 2014; 8: 1665-9.
  • 37. Mansuroglu T, Baumhoer D, Dudas J, et al. Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells. Eur J Gastroenterol Hepat 2009; 21: 1206-11.

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.